上海腾瑞制药股份有限公司

Chinese biopharmaceutical company founded in 2010 and registered in Situan town, Fengxian district, Shanghai, designated a Shanghai high-tech enterprise. Integrates drug research, manufacturing and marketing across biologics, chemical active ingredients and oral solid dosage forms, with a roughly 100 mu GMP production base in the Lin-gang special area of the Shanghai free trade zone. Its lead products are the national class 1 biologic recombinant human acidic fibroblast growth factor for external use, marketed as Aifujifu for wound healing and listed in China's national reimbursement catalogue, and recombinant batroxobin for injection.